| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Y-mAbs Therapeutics, Inc.$8.61
+0.02 (+0.23%)
D 37Pipeline Score Fair Value Pharma · Clinical
Market Cap
391.22 M
EPS
-0.49
P/E Ratio
-
Value Trade
6.54 M
0.35 %
Week
1.18 %
1 Month
74.65 %
3 Month
87.99 %
6 Month
-79.44 %
5 Year
-67.51 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
760.67 K
52 Week Range
3.55 - 16.11
% held by Insiders
24.88 %
% held by Institutions
59.03 %
Enterprise Value
332.06 M
Total Shares
45.44 M
Short %
7.8 %
Float Shares
34.49 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-05-28 | GD2-SADA (Pretargeted Radioimmunotherapy) | phase 1 data readout | Phase 1 | — | – | – | – |
2025-05-28 | GD2-SADA (Pretargeted Radioimmunotherapy) | phase 1 data readout | Phase 1 | — | – | – | – |
2025-05-28 | GD2-SADA (Pretargeted Radioimmunotherapy) | phase 1 data readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
D37
Pipeline Score $609M
Pipeline ValueFair Value
Valuation Signal11
Drugs Scored1.6x
rNPV / MCap Top 50%
Micro Cap (rank 457 of 912)
Percentile RankY-mAbs Therapeutics, Inc. faces pipeline headwinds (37/100), with $2.7B risk-adjusted pipeline value, led by Hu3F8 With GM-CSF in Neuroblastoma (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hu3F8 With GM-CSF Monoclonal antibody | Neuroblastoma | Phase 2 | NCT01757626 | 26% | $532M | ACTIVE NOT_RECRUITING | 245 | - | - | Dec 1, 2026 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
naxitamab | relapsed/refractory high-risk neuroblastoma | Phase 2 | 2025-03-03 | overall response rate: 50%; complete response: 38%; partial response: 12%; bone compartment response: 58%; bone marrow compartment response: 74%; one year overall survival: 93%; one year progression free survival: 35% Read More | Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications Read More | |
naxitamab | relapsed/refractory high-risk neuroblastoma | Phase 2 | 2025-03-03 | overall response rate: 50%; complete response: 38%; partial response: 12%; bone compartment response: 58%; bone marrow compartment response: 74%; one year overall survival: 93%; one year progression free survival: 35% Read More | Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications Read More | |
naxitamab | relapsed/refractory high-risk neuroblastoma | Phase 2 | 2025-03-03 | overall response rate: 50%; complete response: 38%; partial response: 12%; bone compartment response: 58%; bone marrow compartment response: 74%; one year overall survival: 93%; one year progression free survival: 35% Read More | Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in YMAB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
YMAB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How YMAB ranks across every disease it competes inCompetitive Position is a premium feature
See how YMAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial